AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

This was the stock's third consecutive day of losses.

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

A look at the shareholders of AbbVie Inc. (NYSE:ABBV) can tell us which group is most powerful. We can see that institutions ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $185.62 as of June 30th.

AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales, but investors were disappointed as Botox sales ...

AbbVie Inc. agreed to acquire ImmunoGen Inc. for a total equity value of $10.1 billion, delivering the biotech company’s Elahere cancer drug to the pharmaceutical giant.

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. By Rebecca Robbins ...

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim Jan. 6, 2018 ...